Market Pulse Archives

Feb. 27, 2020, 8:30 p.m. EST

Biotech company Forty Seven surges 30% after hours on report of Gilead interest

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Forty Seven Inc. Cl A (FTSV)
  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Mike Murphy

Shares of cancer-therapy company Forty Seven Inc. /zigman2/quotes/209451275/composite FTSV +0.03% shot up more than 30% in after-hours trading Thursday after a report that Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD +1.60% has made a takeover offer. Bloomberg News reported that Gilead and Forty Seven, a biotech firm that specializes in cancer immunotherapy, are discussing a number of options, including a partnership, and the company was said to have other suitors as well. Forty Seven's stock is up 192% over the past year, with a market cap of around $2.3 billion. Gilead shares ticked up slightly in extended trading.

/zigman2/quotes/209451275/composite
US : U.S.: Nasdaq
$ 95.46
+0.03 +0.03%
Volume: 745,677
April 3, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.60 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 78.21
+1.23 +1.60%
Volume: 19.42M
April 3, 2020 4:00p
P/E Ratio
18.58
Dividend Yield
3.48%
Market Cap
$98.47 billion
Rev. per Employee
$2.02M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.